Suppr超能文献

肥胖症的药物治疗

Pharmacotherapy for obesity.

作者信息

Lee Phong Ching, Dixon John

出版信息

Aust Fam Physician. 2017;46(7):472-477.

Abstract

BACKGROUND

Obesity is a serious, chronic, relapsing disease of energy regulation, with strong genetic and early-life environmental determinants. Pharmacotherapy can be a useful adjunct to lifestyle intervention in effecting and maintaining clinically meaningful weight loss.

OBJECTIVE

The aim of this article is to discuss the role of pharmacotherapy in obesity management. The efficacy, side effects and contraindications of available weight-loss medications are reviewed.

DISCUSSION

Long-term pharmacotherapy options, which can be effective in providing moderate weight loss, are available to treat obesity. Pharma-cotherapy should be considered an adjunct to lifestyle intervention in those with a body mass index (BMI) >30 kg/m30 kg/m2, or in those with a BMI of 27-30 kg/m2 and obesity-related complications. Safety and efficacy should be monitored closely on commencement, and the medication should be discontinued if there are safety or tolerability issues, or if.

摘要

背景

肥胖是一种严重的、慢性的、复发性的能量调节疾病,具有强大的遗传和早期生活环境决定因素。药物治疗可作为生活方式干预的有益辅助手段,以实现并维持具有临床意义的体重减轻。

目的

本文旨在探讨药物治疗在肥胖管理中的作用。对现有减肥药物的疗效、副作用和禁忌症进行综述。

讨论

有长期药物治疗方案可用于治疗肥胖,这些方案能有效实现适度体重减轻。对于体重指数(BMI)>30kg/m²的人群,或BMI为27 - 30kg/m²且伴有肥胖相关并发症的人群,药物治疗应被视为生活方式干预的辅助手段。开始治疗时应密切监测安全性和疗效,若出现安全或耐受性问题,或……则应停用药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验